Aurobindo Pharma: Unit 7 gets 9 US FDA observations, shares in focus

• Aurobindo Pharma's Unit-VII, an oral solid dosage manufacturing unit, received nine observations from the US FDA.
• The US FDA conducted inspections from January 28 to February 10, 2026, at the TSIIC, Green Industrial Park facility.
• Form 483 observations can indicate potential violations in facility, equipment, processes, controls, products, employee practices, or records.
• The company previously received 11 observations at its Unit III manufacturing facility.
• Aurobindo Pharma reported a Q3 net profit of ₹909.8 crore, up 7.5% year-on-year, with revenue up 8.4% to ₹8,646 crore.